DE69839347D1 - Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal - Google Patents

Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal

Info

Publication number
DE69839347D1
DE69839347D1 DE69839347T DE69839347T DE69839347D1 DE 69839347 D1 DE69839347 D1 DE 69839347D1 DE 69839347 T DE69839347 T DE 69839347T DE 69839347 T DE69839347 T DE 69839347T DE 69839347 D1 DE69839347 D1 DE 69839347D1
Authority
DE
Germany
Prior art keywords
human brain
potassium channel
kcnq2
biomolecule
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69839347T
Other languages
English (en)
Other versions
DE69839347T2 (de
Inventor
Jayashree Aiyar
Claudia Ann Iannotti
Edward Philip Christian
Naomi Jean Logsdon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69839347D1 publication Critical patent/DE69839347D1/de
Application granted granted Critical
Publication of DE69839347T2 publication Critical patent/DE69839347T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
DE69839347T 1997-12-13 1998-12-11 Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal Expired - Fee Related DE69839347T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9726339.6A GB9726339D0 (en) 1997-12-13 1997-12-13 Human-derived tissue-specific potassium channel
GB9726339 1997-12-13
PCT/GB1998/003720 WO1999031232A1 (en) 1997-12-13 1998-12-11 Human brain derived kcnq2 potassium channel

Publications (2)

Publication Number Publication Date
DE69839347D1 true DE69839347D1 (de) 2008-05-21
DE69839347T2 DE69839347T2 (de) 2009-05-07

Family

ID=10823549

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839347T Expired - Fee Related DE69839347T2 (de) 1997-12-13 1998-12-11 Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal

Country Status (9)

Country Link
US (1) US20060183105A1 (de)
EP (1) EP1036175B1 (de)
JP (1) JP2002508178A (de)
AT (1) ATE391779T1 (de)
AU (1) AU1569599A (de)
DE (1) DE69839347T2 (de)
ES (1) ES2303359T3 (de)
GB (1) GB9726339D0 (de)
WO (1) WO1999031232A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037900A4 (de) 1997-10-24 2006-08-30 Univ Utah Res Found Kcnq2 und kcnq3-kaliumkanalgene welche als mutanten bei gutartigen krämpfen bei neugeborenen und anderen formen von epilepsie vorliegen
US6649371B1 (en) 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
AU783191B2 (en) * 1999-10-08 2005-10-06 Caliper Life Sciences, Inc. Use of nernstein voltage sensitive dyes in measuring transmembrane voltage
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
DE10013732A1 (de) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
DK1539802T3 (da) * 2002-06-25 2007-12-03 Serono Genetics Inst Sa Hidtil ukendte KCNQ polypeptider og deres anvendelse til diagnosen af mentale lidelser
US7442519B2 (en) 2002-06-25 2008-10-28 Serono Genetics Institute, S.A. KCNQ2-15 potassium channel
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
US20140093946A1 (en) * 2012-09-28 2014-04-03 General Electric Company System for optimizing the introduction of nucleic acids into cells using magnetic particles
WO2023283646A1 (en) * 2021-07-08 2023-01-12 Baylor College Of Medicine Recombinant microorganism-based methods and compositions for treatment of disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2240737C (en) * 1995-12-22 2009-09-29 University Of Utah Research Foundation A long qt syndrome gene which encodes kvlqt1 and its association with mink
JPH09191882A (ja) * 1996-01-16 1997-07-29 Japan Tobacco Inc ヒト新規ｋ＋チャネル蛋白質をコードするｄｎａおよびその断片

Also Published As

Publication number Publication date
AU1569599A (en) 1999-07-05
US20060183105A1 (en) 2006-08-17
EP1036175B1 (de) 2008-04-09
WO1999031232A1 (en) 1999-06-24
ES2303359T3 (es) 2008-08-01
DE69839347T2 (de) 2009-05-07
ATE391779T1 (de) 2008-04-15
JP2002508178A (ja) 2002-03-19
GB9726339D0 (en) 1998-02-11
EP1036175A1 (de) 2000-09-20

Similar Documents

Publication Publication Date Title
DE69839347D1 (de) Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal
DE69401230T2 (de) Verwendung von Polyurethanen, die funktionelle Carboxylatogruppe enthalt, zur Haarfestigung
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
DE3280344D1 (de) Verwendung von retinoiden und minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia.
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE219928T1 (de) Verwendung von angiogenese-suppressoren zur hemmung des haarwuchses
ATE213160T1 (de) Verwendung von epinastin für die behandlung von schmerzen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
MY131442A (en) Excitatory amino acid receptor antagonists
DE69532167D1 (de) Inhibitierung des haarwuchses
IL125711A0 (en) Human metabotropic glutamate receptor
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
ATE76570T1 (de) Mittel zur haarbehandlung.
DE69837267D1 (de) Kcnq kaliumkanäle und verfahren zur deren modulierung
DE69625877D1 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
IT8567714A1 (it) Procedimento enzimatico di depilazione di pelli.
EA200001246A1 (ru) Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69940793D1 (de) Chimärisches Gen, dass für die antigenischen Determinanten von vier Proteinen aus L. Infantum kodiert
DE59808165D1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
IT1136983B (it) Procedimento per la preparazione di cuoio e di pelo di animale qualitativamente molto pregiato da pelli grezze
ATE246926T1 (de) Verwendung von 1-ar(alk)yl-imidazolin-2-one zur behandlung von angst- und spannungszuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee